News Headlines

  1. Jubilant HollisterStier Announces First FDA Commercial Product Approval For Sterile Fill-Finish Line 3 9/10/2026

    Jubilant HollisterStier (JHS) is pleased to announce the FDA regulatory approval of the first commercial sterile injectable product manufactured on its Line 3 isolator fill-finish line, marking a major milestone for the company’s expanded manufacturing operations at its Spokane facility.

  2. Insights From GRAM At CPHI Milan 2026: Navigating The Future Of Sterile Manufacturing 9/9/2026

    As biologics manufacturing evolves, Contract Development and Manufacturing Organizations (CDMOs) are becoming increasingly pivotal. At CPHI Milan, October 6 – 8, 2026, Grand River Aseptic Manufacturing (GRAM) will showcase its innovative capabilities, particularly in aligning manufacturing capacity and capabilities with clients’ long-term goals, at booth #8A26.

  3. Ardena To Attend CPHI Worldwide Milan 2026, Launching Charity Step Challenge "From Molecules To Miles" 9/9/2026

    Ardena, a full-service contract development and manufacturing organization (CDMO) supporting pharmaceutical companies from molecule to market, will participate in CPHI Worldwide, taking place October 6-8, 2026, in Milan, Italy.

  4. EpilepsyGTx And Viralgen Collaborate To Advance AAV Gene Therapy Programme For Epilepsy Ahead Of First-In-Human Trial 9/9/2026

    EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract development and manufacturing organization (CDMO) specialising in recombinant adeno-associated virus (AAV) gene therapies, today announced a partnership to support production of EpilepsyGTx's lead investigational gene therapy programme targeting patients with focal refractory epilepsy (FRE), EPY201, ahead of first-in-human clinical trials.

  5. Ratio Therapeutics Enters Into Research Collaboration And License Agreement With RayzeBio To Advance A Novel Radiopharmaceutical Program 9/9/2026

    Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a research collaboration and license agreement with RayzeBio, Inc., a clinical-stage radiopharmaceutical company with a mission to transform the lives of people with cancer, to advance a novel radiopharmaceutical program focused on two undisclosed targets.

  6. Exclusive Partnership With Indovinya In Europe 9/9/2026

    Brenntag, the global market leader in chemicals and ingredients distribution, announced today a new exclusive distribution partnership with Indovinya Belgium N.V., part of the Indorama Group, covering polyethylene glycols (Macrogols) and polysorbates for pharmaceutical and nutraceutical applications.

  7. Transcenta Therapeutics And WuXi Biologics Enter Into Strategic Collaboration To Accelerate Commercialization Of HiCB Continuous Bioprocessing Technologies 9/9/2026

    Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its subsidiary, HJB, have entered into a technology licensing and strategic collaboration agreement with WuXi Biologics.

  8. 1cBio And Lee's Pharmaceutical Holdings Limited Enter Into Exclusive Licensing Agreement To Develop And Commercialize 1cBio's PARP1 Inhibitor OC-3 For Oncology In Greater China And Southeast Asia 9/9/2026

    1cBio, a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases, and Lee's Pharmaceutical Holdings Ltd. ("Lee's Pharm"), today announced that the companies have entered into a licensing agreement granting Lee's Pharm exclusive rights to develop and commercialize 1cBio's lead PARP1 inhibitor, OC-3, in China and certain countries in Southeast Asia.

  9. Matica Biotechnology And Bondwell Technologies Collaborate To Advance Texas Biotech Innovation 9/9/2026

    Matica Biotechnology ("Matica Bio"), a Texas-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced a collaboration with Bondwell Technologies, an innovative Texas biotechnology company developing next generation technologies for bioprocessing and advanced life science applications.

  10. MannKind And Rose Pharma Inc Enter Licensing And Collaboration Agreement To Develop An Inhaled Rapid-Acting, Short-Duration GLP-1 For Weight Management 9/9/2026

    MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management.